MX2023005472A - Formas de dosificacion de liberacion sostenida de una sal de tapentadol con acido l-(+)-tartarico. - Google Patents
Formas de dosificacion de liberacion sostenida de una sal de tapentadol con acido l-(+)-tartarico.Info
- Publication number
- MX2023005472A MX2023005472A MX2023005472A MX2023005472A MX2023005472A MX 2023005472 A MX2023005472 A MX 2023005472A MX 2023005472 A MX2023005472 A MX 2023005472A MX 2023005472 A MX2023005472 A MX 2023005472A MX 2023005472 A MX2023005472 A MX 2023005472A
- Authority
- MX
- Mexico
- Prior art keywords
- tapentadol
- salt
- tartaric acid
- sustained release
- dosage forms
- Prior art date
Links
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 title abstract 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 title abstract 3
- KWTWDQCKEHXFFR-SMDDNHRTSA-N tapentadol Chemical compound CN(C)C[C@H](C)[C@@H](CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-SMDDNHRTSA-N 0.000 title abstract 3
- 229960005126 tapentadol Drugs 0.000 title abstract 3
- 235000011002 L(+)-tartaric acid Nutrition 0.000 title abstract 2
- 239000001358 L(+)-tartaric acid Substances 0.000 title abstract 2
- FEWJPZIEWOKRBE-LWMBPPNESA-N L-(+)-Tartaric acid Natural products OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 title abstract 2
- 238000013268 sustained release Methods 0.000 title abstract 2
- 239000012730 sustained-release form Substances 0.000 title abstract 2
- 239000002552 dosage form Substances 0.000 title 1
- 235000002906 tartaric acid Nutrition 0.000 abstract 1
- 239000011975 tartaric acid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La invención se refiere a un comprimido que proporciona una liberación sostenida de tapentadol, estando el tapentadol contenido en forma de una sal con ácido tartárico, en particular en forma de una sal con ácido L-(+)-tartárico. El comprimido tiene propiedades mecánicas satisfactorias, por ejemplo, en términos de resistencia a la rotura y friabilidad, y puede fabricarse en condiciones de compresión considerablemente simplificadas, en particular con una fuerza de prensado reducida.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20206812 | 2020-11-10 | ||
| EP20206800.3A EP3995135B1 (de) | 2020-11-10 | 2020-11-10 | Darreichungsformen mit verlängerter freisetzung eines salzes von tapentadol mit l-(+)-weinsäure |
| PCT/EP2021/081197 WO2022101247A1 (de) | 2020-11-10 | 2021-11-10 | Darreichungsformen mit verlängerter freisetzung eines salzes von tapentadol mit l-(+)-weinsäure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023005472A true MX2023005472A (es) | 2023-05-22 |
Family
ID=78536235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023005472A MX2023005472A (es) | 2020-11-10 | 2021-11-10 | Formas de dosificacion de liberacion sostenida de una sal de tapentadol con acido l-(+)-tartarico. |
Country Status (4)
| Country | Link |
|---|---|
| CO (1) | CO2023005962A2 (es) |
| MX (1) | MX2023005472A (es) |
| PE (1) | PE20240113A1 (es) |
| WO (1) | WO2022101247A1 (es) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4426245A1 (de) | 1994-07-23 | 1996-02-22 | Gruenenthal Gmbh | 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung |
| PE20030527A1 (es) | 2001-10-24 | 2003-07-26 | Gruenenthal Chemie | Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen |
| KR101204657B1 (ko) | 2004-07-01 | 2012-11-27 | 그뤼넨탈 게엠베하 | (1r,2r)-3-(3-디메틸아미노-1-에틸-2-메틸-프로필)-페놀을 함유하는 남용 방지 경구 투여 제형 |
| MX2009004557A (es) | 2006-10-27 | 2009-05-11 | Janssen Pharmaceutica Nv | Composicion farmaceutica granulada seca y metodos para producirla. |
| JP5774853B2 (ja) | 2008-01-25 | 2015-09-09 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 医薬投薬形 |
| US20160136112A1 (en) | 2013-08-02 | 2016-05-19 | Ratiopharm Gmbh | Composition comprising tapentadol in a dissolved form |
| WO2015157138A1 (en) * | 2014-04-07 | 2015-10-15 | Banner Life Sciences Llc | Abuse-deterrent controlled release formulations |
| EP2942054A1 (en) | 2014-05-09 | 2015-11-11 | G.L. Pharma GmbH | Slow-release pharmaceutical formulation |
| PL3377049T3 (pl) | 2015-11-17 | 2021-06-28 | Msn Laboratories Private Limited | Krystaliczne formy soli tapentadolu i sposób ich wytwarzania |
-
2021
- 2021-11-10 MX MX2023005472A patent/MX2023005472A/es unknown
- 2021-11-10 PE PE2023001584A patent/PE20240113A1/es unknown
- 2021-11-10 WO PCT/EP2021/081197 patent/WO2022101247A1/de active Application Filing
-
2023
- 2023-05-09 CO CONC2023/0005962A patent/CO2023005962A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20240113A1 (es) | 2024-01-22 |
| CO2023005962A2 (es) | 2023-05-19 |
| WO2022101247A1 (de) | 2022-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2010009222A (es) | Soluciones farmaceuticas, proceso de preparacion y usos terapeuticos. | |
| JP2009102341A5 (es) | ||
| MX357314B (es) | Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales. | |
| MX2012003551A (es) | Tabletas transformables via oral. | |
| PE20110119A1 (es) | Asociacion entre ferroquina y artesunato para el tratamiento del paludismo | |
| UA108741C2 (uk) | Фармацевтична композиція для екстреної контрацепції | |
| PH12013501222A1 (en) | Soluble milk-based tablet surface-treated with carbohydrate | |
| MY173730A (en) | Orally-disintegrating solid preparation | |
| SI2150538T1 (sl) | Novi substituirani hidantoini | |
| IN2014DN06966A (es) | ||
| SI2178513T1 (sl) | Tabletni sestavki vsebujoäśi atazanavir | |
| MX341428B (es) | Tableta de liberacion controlada de extracto de ginkgo biloba y procedimiento para su obtencion. | |
| MX2023005472A (es) | Formas de dosificacion de liberacion sostenida de una sal de tapentadol con acido l-(+)-tartarico. | |
| EA201270309A1 (ru) | Таблетки отилония, полученные прямым прессованием | |
| MX2009013504A (es) | Composiciones comprimidas que tienen atazanavir. | |
| MX2009008108A (es) | Composicion farmaceutica que contiene una combinacion de tramadol y ketoprofeno. | |
| IN2014DN06965A (es) | ||
| PH12014501024A1 (en) | Soluble non-dairy creamer tablet surface-treated with carbohydrate | |
| MX2009013499A (es) | Composiciones comprimidas que contienen atazanavir. | |
| MD4375B1 (ro) | Procedeu de sinteză enzimatică a (7S)-1-(3,4-dimetoxibiciclo¢4.2.0]octa-1,3,5-trien-7-il)-N-metil-metanaminei şi aplicarea în sinteza ivabradinei şi a sărurilor sale | |
| MY153610A (en) | Fixed dose combination in form of a bilayered or monolayered tablet of aliskiren and amlodipine | |
| WO2019132579A3 (ko) | 세포질 침투 항체에 융합된 rna 분해효소를 포함하는 면역독소 | |
| PH12014501224B1 (en) | Tablet containing 1-cyclopropyl-8-(difluoromethoxy)-7-[(1r)-1-methyl-2, 3-dihydro-1h-isoindole-5-yl]-4-oxo-1, 4-dihydroquinoline-3-carboxylic acid methanesulfonate hydrate | |
| NZ596541A (en) | Combination therapy for the treatment of multiple myeloma using cep-18770 together with bortezomib or mephalan | |
| MX374866B (es) | Comprimido y método para preparar el mismo. |